The effects of GLP1-RAs on “hard” kidney failure and cardiovascular outcomes, specifically in patients with T2DM and CKD are currently under investigation in the ongoing FLOW (A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney) trial [45]. Here, GLP1R is linked to chronic kidney disease.